Pharmaceutical - Inflammatory diseases, Regulation


Popular Filters

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III


US pharma major Eli Lilly’s investigational medicine ixekizumab was superior to etanercept and placebo…

Eli LillyInflammatory diseasesixekizumabPharmaceuticalRegulationResearch

Review of ibuprofen medicines started by EMA Pharmacovigilance unit

Review of ibuprofen medicines started by EMA Pharmacovigilance unit


At its June 2014 meeting, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee…

EuropeibuprofenInflammatory diseasesNeurologicalPharmaceuticalRegulation

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis


US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

Insmed’s mixed results from Ph II trial for treatment resistant NTM lung infections


US-based Insmed has reported mixed results from its Phase II clinical trial of Arikayce, for the treatment…

Inflammatory diseasesInsmedPharmaceuticalRegulationRespiratory and PulmonaryUSA

Novartis gains breakthrough therapy designation for sIBM drug from US FDA


Swiss drug major Novartis (NOVN: VX) has gained US Food and Drug Administration breakthrough therapy…

bimagrumabInflammatory diseasesNorth AmericaNovartisPharmaceuticalRegulation

SOBI gets FDA approval to manufacture substance for Kineret with partner Boehringer Ingelheim


Swedish Orphan Biovitrum (STO: SOBI) said today (June 11) that it has received approval from the US Food…

Boehringer IngelheimInflammatory diseasesKineretNorth AmericaPharmaceuticalProductionRegulationSavient PharmaceuticalsSwedish Orphan Biovitrum

In Japan, Mitsubishi Tanabe files for canagliflozin approval; Eisai/AbbVie's Humira gets new indication


Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) said yesterday (May 27) that it has submitted…

AbbVieAsia-PacificBiotechnologycanagliflozinDiabetesEisaiHumiraInflammatory diseasesInvokanaMitsubishi TanabePharmaceuticalRegulation

US FDA approves Janssen's Simponi to treat ulcerative colitis


The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Positive opinions for Novartis' Jetrea and Ilaris from EMA advisory panel


Among a number of positive recommendations last Friday from the European Medicines Agency's Committee…

Anti-Arthritics/RheumaticsEuropeIlarisInflammatory diseasesJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Savient's Krystexxa gets final EU approval for chronic tophaceous gout


US drugmaker Savient Pharmaceuticals (Nasdaq: SVNT) says that the European Commission has granted a marketing…

EuropeInflammatory diseasesKrystexxaPharmaceuticalRegulationSavient Pharmaceuticals

EMA reviews hypothesis on Pandemrix hypothesis; finalizes on NSAIDs and CV events


The European Medicines Agency's Committee on Human Medicinal Products (CHMP) said Friday that it has…

Anti-Arthritics/RheumaticsdiclofenacGlaxoSmithKlineibuprofenInflammatory diseasesNaproxenNeurologicalPandemrixPharmaceuticalRegulationVaccines

Abbott's Humira OKed for new ulcerative colitis indication in EU


Following a previous favorable advisory committee recommendation, US health care major Abbott Laboratories…

Abbott LaboratoriesEuropeGastro-intestinalsHumiraInflammatory diseasesPharmaceuticalRegulation

Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex


In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

EuropeInflammatory diseasesPfizerPharmaceuticalRegulationXiapex




Back to top